Dit is volgens mij de hele trail. Pagina 203.
HEYDENS, WILLIAM F [AG/1000]
From : SALTMIRAS, DAVID A [AG/1000]
Sent: Thursday, February 19, 2015 4:01 PM
To: HEYDENS, WILLIAM F [AG/1000]; FARMER, DONNA R [AG/1000]
Cc: KOCH, MICHAEL S [AG/1000]; HODGE-BELL, KIMBERLY C [AG/1000]
Subject : RE: IARC Planning
Bill et al.,
I had an extended chat with Roger this afternoon, as is the custom. He said that Critical Reviews has already dedicated
some significant space to the glyphosate topic, especially the pending issue #3 with both the carc paper & Kier paper.
However, to the contrary, he did say he'd consider something along the lines of the 1, 3 - butadiene issue... I think we
would have to prepare a very compelling story.
DavidSa(tmiras, Ph-D., D._,^L.B.'
Science Fellow
Novel Chemistry and Microbials Product Lead
Toxicology and Nutrition Center
Monsanto
ph (314) 694-8856
From : HEYDENS, WILLIAM F [AG/1000]
Sent: Thursday, February 19, 2015 7:53 AM
To: FARMER, DONNA R [AG/1000]
Cc: KOCH, MICHAEL S [AG/1000]; SALTMIRAS, DAVID A [AG/1000]; HODGE-BELL, KIMBERLY C [AG/1000]
Subject: RE: IARC Planning
Donna,
Per our phone call with John the other day, the next two most important things that we need to do are
the Meta-analysis publication and the Ag Health Study Follow-up publication, assuming we can get our
hands on the data in a reasonable timeframe. I feel confident that we will have organizational support
for doing these projects, so I think we need to start setting them up now.
For the meta-analysis, please contact Elizabeth, let her know we would like her/Ellen to do this, and
get a cost estimate from her.
For the AHS data, I heard 2 action items during our call: first - get with the lawyers to initiate the FOI
process; second - contact Tom Sorohan and get him lined up to do the analysis when we get the data;
also, get a cost estimate from him.
For the overall plausibility paper that we discussed with John (where he gave the butadiene example),
I'm still having a little trouble wrapping my mind around that. If we went full-bore, involving experts
from all the major areas (Epi, Tox, Genetox, MOA, Exposure - not sure who we'd get), we could be
pushing $250K or maybe even more. A less expensive/more palatable approach might be to involve
experts only for the areas of contention, epidemiology and possibly MOA (depending on what comes
out of the IARC meeting), and we ghost-write the Exposure Tox & Genetox sections. An option would
be to add Greim and Kier or Kirkland to have their names on the publication, but we would be keeping
the cost down by us doing the writing and they would just edit & sign their names so to speak. Recall
that is how we handled Williams Kroes & Munro, 2000.
1
Confidential - Produced Subject to Protective Order MONGLY00977267
Case 3:16-md-02741-VC Document 187-12 Filed 03/14/17 Page 4 of 7
One thing we could do now on this is to contact Roger McClellan at CRC and see if they would be
amenable to putting this publication in Crit. Rev. Toxicol. John said he knew that Roger had done such a
publication in the past . David , since you have worked with Roger on the other papers, would you be
willing to contact him to judge his willingness to publish such a paper?
Any other thoughts welcomed.
From : HEYDENS, WILLIAM F [AG/1000]
Sent : Tuesday, February 17, 2015 4:53 PM
To: KOCH, MICHAEL S [AG/1000]; FARMER, DONNA R [AG/1000]; SALTMIRAS, DAVID A [AG/1000]; GARNETT,
RICHARD P [AG/5040]; GUSTIN, CHRISTOPHE [AG/5040]; LISTELLO, JENNIFER J [AG/1000]
Cc: HEYDENS, WILLIAM F [AG/1000]
Subject: IARC Planning
Attached is an updated spreadsheet for our IARC preparations.
Please let me know if you have any additions /corrections . Ongoing Activities are indicated by light blue
fill color.
We did not have our IARC Planning meeting Monday due to the site being closed . However, Donna
and I had a phone conference with John Acquavella today, and this resulted in several additions which
are on page 4 of the attached Work Plan document.
Please let me know if you have other ideas or comments.
Thanks.
Bill
2
Er zijn meer emails met hetzelfde subject, dus ik weet niet precies wanneer het begint en ophoudt.